News and Announcements
Global Drug Giant Merck is Investing in Australian Biopharmaceutical Bionomics
- Published October 09, 2015 2:36PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
8th October 2015, By Chris Pash, Business Insider
Global drug giant Merck & Co has made a strategic investment in an Australia biopharmaceutical company Bionomics, which works on the discovery and development of treatment for cancer and diseases of the central nervous system.
Merck, one of the largest pharmaceutical companies in the world, is buying 21,659,230 million shares at $0.5938, a 29% premium to Bionomics’ closing price on Wednesday, a total investment of about $12.8 million.
The news sent Bionomics shares more than 18% higher to $0.545.
To read the full story, please click here.
Company Updates
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Backed By Leading Investment Groups and Family Offices
